Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Artif Intell Med Imaging. Jun 28, 2021; 2(3): 64-72
Published online Jun 28, 2021. doi: 10.35711/aimi.v2.i3.64
Published online Jun 28, 2021. doi: 10.35711/aimi.v2.i3.64
Application of radiomics in hepatocellular carcinoma: A review
Zhi-Cheng Jin, Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, Jiangsu Province, China
Bin-Yan Zhong, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China
Author contributions: Jin ZC and Zhong BY contributed to study design, review of literature, interpretation of data, and drafting and revision of the manuscript.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bin-Yan Zhong, MD, PhD, Doctor, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215006, Jiangsu Province, China. byzhongir@sina.com
Received: May 13, 2021
Peer-review started: May 13, 2021
First decision: June 2, 2021
Revised: June 19, 2021
Accepted: June 30, 2021
Article in press: June 30, 2021
Published online: June 28, 2021
Peer-review started: May 13, 2021
First decision: June 2, 2021
Revised: June 19, 2021
Accepted: June 30, 2021
Article in press: June 30, 2021
Published online: June 28, 2021
Core Tip
Core Tip: The high molecular heterogeneity in hepatocellular carcinoma poses huge challenges for clinical practice or trial design and has become a major barrier to improving the management of hepatocellular carcinoma. Radiomics could quantify tumoral phenotypes and heterogeneity, which may provide benefits in clinical decision-making at a lower cost. Here, we review the workflow and application of radiomics in hepatocellular carcinoma.